Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067389 · ClinicalTrials.gov registry record
Combined Breast Cancer Risk Study
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 553
- Enrollment target
NCT03067389: Completed study, sponsored by Myriad Genetic Laboratories.
NCT03067389 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 553 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03067389 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 553 participants
- Enrollment target
Study Summary
A prospective, non-interventional study in women 18 to 84 years of age. Subjects will provide a sample for genetic testing and information about their medical and family history. The results of the genetic test will be combined with clinical data to validate a method of predicting breast cancer risk.
Interventions
- DIAGNOSTIC_TEST Diagnostic test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2016-02-06 |
| Est. Completion | 2019-01-08 |
What the finished NCT03067389 record still lists
NCT03067389 is an observational study that tracks outcomes without assigning an intervention. The registered 553 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic test is the first listed.
NCT03067389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03067389 about?
NCT03067389 is a clinical study titled "Combined Breast Cancer Risk Study". A prospective, non-interventional study in women 18 to 84 years of age. Subjects will provide a sample for genetic testing and information about their medical and family history. The results of the genetic test will be combined with clinical data to validate a method of predicting breast cancer risk...
What is the current status of trial NCT03067389?
This trial is currently completed. The enrollment target is 553 participants. The study started on 2016-02-06. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT03067389?
The interventions under investigation include: Diagnostic test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03067389?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI